Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK2 | O00142 | 4/20 | 0.41 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.37 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20518491 | 0.89 | TK2 (0.41) | TK2RNASE1ABCG2ABCB1CA12 | |
| SCHEMBL29529114 | 0.82 | TK2 (0.40) | TK2RNASE1CA12CA5ACA7 | |
| SCHEMBL20518472 | 0.78 | TK2 (0.39) | TK2RNASE1CA12CA5ACA7 | |
| SCHEMBL29834210 | 0.78 | TK2 (0.42) | TK2ABCG2ABCB1 | |
| SCHEMBL21625671 | 0.78 | TK2 (0.62) | TK2RNASE1 | |
| SCHEMBL30679319 | 0.77 | TK2 (0.40) | TK2RNASE1ABCG2ABCB1CA12 | |
| SCHEMBL29529678 | 0.74 | TK2 (0.39) | TK2RNASE1CA12CA5ACA7 | |
| SCHEMBL8356495 | 0.74 | TK1 (0.47) | RNASE1 | |
| SCHEMBL30937946 | 0.73 | KDM4E (0.45) | — | |
| SCHEMBL30608669 | 0.72 | TK2 (0.39) | TK2RNASE1ABCG2ABCB1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12209106-B2 | Alkoxyphenyl derivatives, protected nucleosides and protected nucleotides, method for producing oligonucleotides, and method for removing substituents | FUJIMOTO CHEMICALS CO., LTD. (KR) | 2025-01-28 | — | — | US | disclosed |
| US-20240239834-A1 | ALKOXYPHENYL DERIVATIVES, PROTECTED NUCLEOSIDES AND PROTECTED NUCLEOTIDES, METHOD FOR PRODUCING OLIGONUCLEOTIDES, AND METHOD FOR REMOVING SUBSTITUENTS | FUJIMOTO CHEMICALS CO., LTD., (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20210317159-A1 | ALKOXYPHENYL DERIVATIVES, PROTECTED NUCLEOSIDES AND PROTECTED NUCLEOTIDES, METHOD FOR PRODUCING OLIGONUCLEOTIDES, AND METHOD FOR REMOVING SUBSTITUENTS | FUJIMOTO CHEMICALS CO., LTD. (JP) | 2021-10-14 | — | — | US | disclosed |
| EP-3825300-A1 | ALKOXYPHENYL DERIVATIVE, NUCLEOSIDE PROTECTOR, NUCLEOTIDE PROTECTOR, METHOD FOR PRODUCING OLIGONUCLEOTIDE, AND METHOD FOR REMOVING SUBSTITUENT | Fujimoto Chemicals Co. Ltd. (JP) | 2021-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239834-A1 | ALKOXYPHENYL DERIVATIVES, PROTECTED NUCLEOSIDES AND PROTECTED NUCLEOTIDES, METHOD FOR PRODUCING OLIGONUCLEOTIDES, AND METHOD FOR REMOVING SUBSTITUENTS | ROS1, POLN, RNMT | TK2 128/4885RNASE1 83/4885ABCG2 3014/4885 |
| US-20210317159-A1 | ALKOXYPHENYL DERIVATIVES, PROTECTED NUCLEOSIDES AND PROTECTED NUCLEOTIDES, METHOD FOR PRODUCING OLIGONUCLEOTIDES, AND METHOD FOR REMOVING SUBSTITUENTS | ROS1, POLN, RNMT | TK2 128/4885RNASE1 83/4885ABCG2 3014/4885 |
| US-12209106-B2 | Alkoxyphenyl derivatives, protected nucleosides and protected nucleotides, method for producing oligonucleotides, and method for removing substituents | ROS1, POLN, RNMT | TK2 128/4885RNASE1 83/4885ABCG2 3014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.